Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-707-8 | CAS number: 29590-42-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP Study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- 1. Temporary deviations from the maximum humidity occurred in teh animal room. Lab data do not indicate an effect of the dviations. 2. In the second wek of treatment, test substance used for formulations was inadverrently stored at room temperature in
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- MTDID 7819
- IUPAC Name:
- MTDID 7819
- Details on test material:
- - Name of test material (as cited in study report: mtdid 7819
- Molecular formula (if other than submission substance): CnH(2n+1)-O-CO=CH2
- Physical state: Clear colorless liquid
- Analytical purity: 99% with a C8 acrylate content of 92%
- Lot/batch no.: 4/2009
- Expiration date of the lot/batch: 01 April 2011
- Radiochemical purity (if radiolabelling):
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: 6 weeks
- Housing:Animals were group housed in macrolon cages with setrilized houseing as bedding and paper as cage enrichment.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: At least 5 days prior to the start of treatment
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.2-22.0 C
- Humidity (%): 41-78%
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light 12 hours light/ 12 hours dark with temporary fluctuations (1 hour max) dues to pupullary rflex tesets and/or ophthalmoscopic exam.):
IN-LIFE DATES: From: 21 August 2009 To: 18 September 2009
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): Test article solubility in vehicle
- Concentration in vehicle: 10-333 mg/ml resulting in doses of 0 (control), 30,300 and 1000 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dosing samples were prepared within 6 hours of dosing. Samplese were analyzed on a single occasion during the in-life phase for homgeneity and accuracy of prparation (all concentrations). Accuracy was acceptable is the mean measured concentrations were 90-110% of the target concentration.
- Duration of treatment / exposure:
- 28 Days
- Frequency of treatment:
- Daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Bsed on results of a 5 day range finding study. Animals in main study were doses at 0 (control), 30, 300 and 1000 mg/kg/day
- Rationale for animal assignment (if not random): random - Positive control:
- corn oil
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice Daily
- Cage side observations checked in table [No.?] were included. Yes
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once Daily
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes / No / No data
- Time schedule for examinations:
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Collected from all surving animals prior to post mortem exam
- Anaesthetic used for blood collection: Yes iso-flurane
- Animals fasted: Yes
- How many animals: All surviving
- Parameters checked in table [No.1] were examined. Yes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Same as haematology
- Animals fasted: Yes
- How many animals: all surviving
- Parameters checked in table [No.2] were examined.
URINALYSIS: No
- Time schedule for collection of urine:
- Metabolism cages used for collection of urine: Yes / No / No data
- Animals fasted: Yes / No / No data
- Parameters checked in table [No.?] were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During week 4 of treatment
- Dose groups that were examined: all animals
- Battery of functions tested: grip strength: other: hearing ability, pupillary reflex, static righting reflex,
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes see Table 3 All tissue samples in groups 1 and 4 (control and hight dose) were examined by the pathologist. In addition, the thyroid, kidneys, stomach and liver in groups 2 and 3 males and females (stomach and liver only for females) were also examined by the pathologist.
HISTOPATHOLOGY: Yes see Table 4
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
BODY WEIGHT AND WEIGHT GAIN
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
FOOD EFFICIENCY
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
OPHTHALMOSCOPIC EXAMINATION
HAEMATOLOGY
CLINICAL CHEMISTRY:
Higher bilirubin in males at 1000 mg/kg
Higher cholesterol levels in females at 300 1000 mg/kg
Lower cholesterol in males at 1000 mg/kg
Higher postssium levels in males and females at 1000 mg/kg
Higher inforganix phosphate in males at 1000 mg/kg
URINALYSIS
NEUROBEHAVIOUR
ORGAN WEIGHTS
Higher liver weight and liver to body weight ration in males at 300(not statistically significant for liver weight) and males and females at 1000 mg/kg
Higher thyroid and thyroid to body weight ratio in males and females at 1000 mg/kg
Higher kidney weight and kidney to body weight ratio in one male (no 17) at 1000 mg/kg
GROSS PATHOLOGY
Kidneys in one male at 300 mg/kg and two males at 1000 mg/kg had pale discoloration of the kidneys. One male at 1000 mg/kg (no 17) had grey-white/dark red, part firm/part soft nodules on teh left kidney which was enlarged in size.
HISTOPATHOLOGY: NON-NEOPLASTIC
HISTOPATHOLOGY: NEOPLASTIC (if applicable)
Stomach: Hyperplasia of teh squamous epithelium of the forestomach was recorded in 2/5 females at 300 mg/kg(minimal) and in 2/5 males (minimal) and 3/5 females (minmal-slight) at 1000 mg/kg.
Liver: Hypertrophy of the hepatoxytes of teh centrilobular are(minimal-slight) was recorded in 4/5 males at 1000 mg/kg
Kidneys: Cortical hyaline droplets in teh kidneys were recorded in 4/5 males at 300 mg/kg (minimal-slight) and 5/5 males at 1000 mg/kg (slight-moderate). This was the microscopic correlate to teh pale kiscoloration recroded at necropsy. The occurrence of cortical hyaline droplets was accompanied by an increased incidence and severity of corticomedullary tubular basophilia in males at 1000 mg/kg (4/5 animals minimal-slight)
Thyroid: A slightly increased incidence and severity of hypertrophy /hyperplasia of teh follicular epithelium as recorded in males at 1000 mg/kg (4/5 animals, moderate-slight)
HISTORICAL CONTROL DATA (if applicable)
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- NOAEL of 30 mg/kg established in the study but the effects are rodent specific and of no relevance to human risk assessment. Based on the results of the study, the human-relevant No Observed Adverse Effect Level is 1000 mg/kg-day.
- Executive summary:
The repeated-dose oral toxicity potential of MTDID 7819 (clear colorless liquid, lot 4/2009) was evaluated in male and female Wistar rats. METHODS: This study was performed in compliance with OECD GLP (1997). The study design was based on the following guidelines: EC No. 440/2008 B.7 (2008), OECD 407 (2008) and OPPTS 870.3050 EPA 712-C-00-366 (2000). MTDID 7819 was prepared in corn oil (vehicle) within 6 hours prior to dosing. Rats (5/sex/group) received 0 (vehicle), 30, 300 or 1000 mg/kg-day MTDID 7819 via oral gavage for 28 days. Parameters evaluated: clinical observations (daily), functional observations (week 4), body weight (weekly), food consumption (weekly), clinical pathology (termination), macroscopic examination (termination), organ weights and microscopic examination of specific tissues. RESULTS: No toxicologically-relevant changes were noted for clinical observations, functional observations, body weights, food consumption or hematology. Adaptive liver changes included increased liver weights (300 mg/kg-day males and 1000 mg/kg-day males and females); centrilobular hepatocellular hypertrophy (1000 mg/kg-day males); total bilirubin, cholesterol, potassium, and/or inorganic phosphate concentrations (1000 mg/kg-day males and females); and cholesterol changes in 300 mg/kg-day females. Although these changes were adaptive, the report authors considered the magnitude of the liver weight increase in the 1000 mg/kg-day-treated animals (i.e. >20%) to be adverse. Adaptive thyroid changes included increased thyroid weights (1000 mg/kg-day males and females); and increased incidence and severity of thyroid follicular epithelium hypertrophy/hyperplasia (1000 mg/kg-day males). Hyperplasia was noted in the forestomach of 300 mg/kg-day-treated females and males and females at 1000 mg/kg-day. The hyperplasia was considered an adaptive response to local irritation in the forestomach and is a common adaptive phenomenon in rat studies. Hyaline droplet formation was noted in the kidneys of the 300 and 1000 mg/kg-day-treated male rats. This result is attributed to the male rat-specific alpha-2u-globulin protein and is not considered relevant for female rats or higher species, including humans. Nephroblastoma correlated with nodules and higher kidney weight in one 1000 mg/kg-day-treated male rat which was considered spontaneous and not related to the test article. CONCLUSION: Based on the results of this study, the authors proposed a rat NOAEL of 30 mg/kg-day. The findings at 300 mg/kg-day were considered rat-specific and of no relevance to humans. Based on the results of the study, the human-relevant No Observed Adverse Effect Level is 1000 mg/kg-day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
